沙美特罗替卡松联合孟鲁司特对咳嗽变异性哮喘患者炎症因子水平及肺功能的影响

Effects of salmeterol fluticasone combined with montelukast on inflammatory factor levels and pulmonary functions in patients with cough variant asthma

目的:分析沙美特罗替卡松联合孟鲁司特对咳嗽变异性哮喘患者炎症因子水平及肺功能的影响。方法:将本院接受治疗的104例咳嗽变异性哮喘患者按随机数字表法分成两组,每组52例。对照组用沙美特罗替卡松治疗,观察组用沙美特罗替卡松联合孟鲁司特治疗。比较两组治疗前、治疗2个月后血清炎症因子[白细胞介素(IL)-17、肿瘤坏死因子(TNF)-α]水平、肺功能[肺活量(VC)、第1 s用力呼气容积(FEV1)、最大通气量(MVV)、用力肺活量(FVC)]与不良反应发生率。结果:相较于治疗前,两组治疗2个月后血清IL-17、TNF-α含量均减少,且观察组低于对照组,差异有统计学意义(P<0.05);相较于治疗前,两组治疗2个月后VC、FEV1、MVV、FVC值均增高,且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应总发生率略高于对照组,差异无统计学意义(P>0.05)。结论:咳嗽变异性哮喘患者接受沙美特罗替卡松、孟鲁司特联合治疗效果确切,安全性高,能减少血清炎症因子含量,利于改善肺功能。

Objective:To analyze the effects of salmeterol fluticasone combined with montelukast on inflammatory factor levels and lung functions in patients with cough variant asthma.Methods:104 patients with cough variant asthma treated in our hospital were randomized into two groups with 52 cases each.Patients in the control group was administered with salmeterol fluticasone,while the combination of salmeterol fluticasone with montelukast for patients in the observation group.Serum inflammatory factors of interleukin(IL)-17 and tumor necrosis factor(TNF)-αlevels,pulmonary functions including lung capacity(VC),forced expiratory volume at the first second(FEV1),maximum ventilation(MVV),forced vital capacity(FVC),and incidence of adverse reactions of both groups were compared before treatment and 2 months after treatment.Results:Compared with those before treatment,serum IL-17 and TNF-αlevels decreased after 2 months of treatment,and lower than those of the control group,which were of statistical significances(P<0.05);compared with those before treatment,the values of VC,FEV1,MVV and FVC of the observation group increased,and was higher than those of the control group.The differences were statistically significant(P<0.05).Though the total incidence of adverse reactions in the observation group was slightly higher,there was no statistical significance between both groups(P>0.05).Conclusion:The combination of salmeterol fluticasone combined with montelukast in patients with cough variant asthma has a clear and safe effect,which can reduce the serum inflammatory factor content and improve lung functions.